IONIS PHARMACEUTICALS ($IONS) posted quarterly earnings results for Q1 2026 on Wednesday, April 29th. The company reported earnings of -$0.30 per share, beating estimates of -$0.92 by $0.62. The company also reported revenue of $246,000,000, beating estimates of $199,540,243 by $46,459,757.
You can see Quiver Quantitative's $IONS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
IONIS PHARMACEUTICALS Insider Trading Activity
IONIS PHARMACEUTICALS insiders have traded $IONS stock on the open market 90 times in the past 6 months. Of those trades, 0 have been purchases and 90 have been sales.
Here’s a breakdown of recent trading of $IONS stock by insiders over the last 6 months:
- ELIZABETH L HOUGEN (EVP, Finance & CFO) has made 0 purchases and 5 sales selling 245,130 shares for an estimated $17,867,370.
- C FRANK BENNETT (EVP, Chief Scientific Officer) has made 0 purchases and 8 sales selling 185,040 shares for an estimated $14,960,646.
- BRETT P MONIA (Chief Executive Officer) has made 0 purchases and 3 sales selling 136,434 shares for an estimated $11,028,423.
- RICHARD S GEARY (EVP, Chief Development Officer) has made 0 purchases and 9 sales selling 125,568 shares for an estimated $9,451,247.
- SHANNON L. DEVERS (EVP, Chief Human Resources Ofc) has made 0 purchases and 12 sales selling 99,605 shares for an estimated $8,130,966.
- ERIC SWAYZE (EVP Research) has made 0 purchases and 7 sales selling 55,217 shares for an estimated $4,396,067.
- ALLENE M. DIAZ has made 0 purchases and 3 sales selling 54,878 shares for an estimated $4,354,428.
- JOSEPH III KLEIN has made 0 purchases and 8 sales selling 55,653 shares for an estimated $4,342,483.
- JOSEPH H WENDER has made 0 purchases and 6 sales selling 56,000 shares for an estimated $4,335,425.
- JOAN E HERMAN has made 0 purchases and 2 sales selling 44,000 shares for an estimated $3,173,830.
- JOSEPH BAROLDI (EVP, Chief Business Officer) has made 0 purchases and 9 sales selling 25,630 shares for an estimated $1,999,579.
- BRIAN BIRCHLER (EVP, Corp and Development Ops) has made 0 purchases and 4 sales selling 23,632 shares for an estimated $1,832,375.
- EUGENE SCHNEIDER (EVP, Chf Clinical Develop Ofcr) has made 0 purchases and 3 sales selling 21,293 shares for an estimated $1,631,254.
- JOSEPH LOSCALZO has made 0 purchases and 3 sales selling 17,032 shares for an estimated $1,284,501.
- PATRICK R. O'NEIL (EVP CLO & General Counsel) has made 0 purchases and 2 sales selling 15,370 shares for an estimated $1,213,198.
- B LYNNE PARSHALL has made 0 purchases and 3 sales selling 10,000 shares for an estimated $794,955.
- KYLE JENNE (EVP, Chf GL Pdt Str Ofcr) has made 0 purchases and 2 sales selling 6,725 shares for an estimated $506,963.
- HOLLY B. KORDASIEWICZ (EVP, Chief Development Officer) sold 4,141 shares for an estimated $313,308
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
IONIS PHARMACEUTICALS Hedge Fund Activity
We have seen 253 institutional investors add shares of IONIS PHARMACEUTICALS stock to their portfolio, and 203 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 7,367,066 shares (-56.0%) from their portfolio in Q4 2025, for an estimated $582,808,591
- CAPITAL WORLD INVESTORS added 5,238,571 shares (+41.2%) to their portfolio in Q4 2025, for an estimated $414,423,351
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 3,228,097 shares (-69.9%) from their portfolio in Q4 2025, for an estimated $255,374,753
- DEEP TRACK CAPITAL, LP removed 2,108,144 shares (-55.4%) from their portfolio in Q4 2025, for an estimated $166,775,271
- JPMORGAN CHASE & CO added 1,760,324 shares (+323.3%) to their portfolio in Q4 2025, for an estimated $139,259,231
- BELLEVUE GROUP AG removed 1,442,252 shares (-23.1%) from their portfolio in Q4 2025, for an estimated $114,096,555
- FRANKLIN RESOURCES INC added 1,314,752 shares (+19941.6%) to their portfolio in Q4 2025, for an estimated $104,010,030
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
IONIS PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $IONS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/10/2025
- Piper Sandler issued a "Overweight" rating on 11/04/2025
To track analyst ratings and price targets for IONIS PHARMACEUTICALS, check out Quiver Quantitative's $IONS forecast page.
IONIS PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $IONS recently. We have seen 12 analysts offer price targets for $IONS in the last 6 months, with a median target of $105.5.
Here are some recent targets:
- Yaron Werber from TD Cowen set a target price of $108.0 on 04/23/2026
- Michael Ulz from Morgan Stanley set a target price of $130.0 on 04/21/2026
- Gary Nachman from Canaccord Genuity set a target price of $110.0 on 04/21/2026
- Jason Gerberry from B of A Securities set a target price of $111.0 on 04/09/2026
- Eliana Merle from Barclays set a target price of $106.0 on 03/26/2026
- Joseph Stringer from Needham set a target price of $105.0 on 03/25/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $120.0 on 03/25/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
